Every lot is tried & tested in a relevant biological assay.
Our Bioassay
- Parks, D.J. et al. (2011) J. Med. Chem. 54, 233.
- Alomone Labs TC-I 2014 inhibits TRPM8 channels expressed in HEK-293 cells.Dose response curve of TRPM8 inhibition by TC-I 2014 (#T-200), showing nearly complete inhibition at 1 µM. Cells were loaded with Calcium-5 dye, incubated for 10 min with increasing concentrations of TC-I 2014, and activated by 30 nM Icilin. Changes in intracellular Ca2+ following agonist application were detected as changes in 485 nm/525 nm fluorescence (RFU).
- Parks, D.J. et al. (2011) J. Med. Chem. 54, 233.
- Behrendt, H.J. et al. (2004) Br. J. Pharmacol. 141, 737.
TC-I 2014 is a selective TRPM8 channel blocker. The compound shows high affinity towards TRPM8 and exhibits in vitro functional activity and good oral efficacy in an inflammatory model of neuropathic pain1. TC-I 2014 inhibits canine, rat, and human TRPM8 mediated Ca2+ influx functional assays with IC50 values of 0.8, 4.0, and 3.0 nM, respectively1.
TRPM8 channel is a member of the TRP channels superfamily. TRPM8 is a Ca2+-permeable, nonselective cation channel that is activated by temperatures in the range of 8–28°C and by chemical agonists such as menthol and icilin. The channel is specifically expressed in temperature-sensing trigeminal and dorsal root ganglion neurons. Its expression is up-regulated in prostate cancer and other malignancies1,2.
TC-l-2014 (#T-200) is a highly pure, synthetic, and biologically active compound.
Applications
Citations
Specifications
Scientific Background
Related Products
Need Help With This Product?
Our reagent specialists are here to help you find the best product for your application. Please call or email us and we will be happy to help you find the right product for the job.
Call us at
+972 2587 2202 or Email Us